No Data
No Data
No Data
No Data
No Data
Rhythm Biosciences Appoints CEO; Shares Down 3%
Rhythm Biosciences (ASX:RHY) appointed David Atkins as chief executive, effective May 13. Atkins has experience across a broad range of life sciences and healthcare disciplines, according to a Wednesd
MT NewswiresApr 24 09:39
Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3%
Rhythm Biosciences (ASX:RHY) received AU$2.5 million under its nonrenounceable rights issue. Shares and options under the rights issue will be allotted March 21 and start trading March 22, according t
MT NewswiresMar 21 11:51
Rhythm Biosciences Seeks to Raise AU$6.6 Million Via Rights Offer; Shares Fall 29%
Rhythm Biosciences (ASX:RHY) is undertaking a 3-for-10 nonrenounceable rights issue at AU$0.10 apiece to raise about AU$6.6 million. Proceeds will be used to transition the current ColoSTAT test to th
MT NewswiresFeb 9 13:12
Companies Like Rhythm Biosciences (ASX:RHY) Could Be Quite Risky
Yahoo FinanceDec 31, 2023 06:32
Rhythm Biosciences Identifies Lung Cancer Biomarkers From Blood Samples; Shares Fall 6%
Rhythm Biosciences (ASX:RHY) identified potential lung cancer biomarkers following a study conducted by bioanalytical partner the Baker Institute, the diagnostic firm said on Friday. The study analyze
MT NewswiresNov 24, 2023 11:13
Rhythm Biosciences Receives First Tranche of R&D Tax Rebate
Medical diagnostics company Rhythm Biosciences (ASX:RHY) received the first tranche of AU$1.7 million in research and development tax incentive. The second tranche of the tax rebate is expected in 202
MT NewswiresNov 14, 2023 15:41
No Data
No Data